Eli Lilly's GLP-1 Drugs Drive Revenue Growth, With Potential for Further Expansion
Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, generated $12.8 billion in revenue during Q1 2026, contributing to a 56% revenue increase. The company has significant growth potential, particularly in international markets and with its upcoming weight loss drug, Eloralintide.
Tickers: $LLY
Topics: Eli Lilly GLP-1 drugs Mounjaro Pharmaceutical Industry Revenue Growth Zepbound